The FDA has approved Yeztugo, a new injectable shot for HIV prevention, announced by Gilead Sciences on Wednesday. This is the first shot of its kind, administered twice a year, and it reduces the risk of sexually acquired HIV in adults and adolescents. Gilead’s CEO, Daniel O’Day, called it a historic day in the fight against HIV. Clinical studies show it has remarkable outcomes and is nearly 100% effective, outperforming daily oral medications like Truvada. The drug requires a negative HIV-1 test before treatment and may cause mild side effects such as injection site reactions, headache, and nausea.